Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford...